Literature DB >> 27659046

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.

Thomas Horn1, Stéphane Ferretti2, Nicolas Ebel2, Angela Tam1, Samuel Ho3, Fred Harbinski4, Ali Farsidjani3, Matthew Zubrowski1, William R Sellers3, Robert Schlegel1, Dale Porter1, Erick Morris1, Jens Wuerthner2, Sébastien Jeay2, Joel Greshock1, Ensar Halilovic1, Levi A Garraway5, Giordano Caponigro6, Joseph Lehár6.   

Abstract

Like classical chemotherapy regimens used to treat cancer, targeted therapies will also rely upon polypharmacology, but tools are still lacking to predict which combinations of molecularly targeted drugs may be most efficacious. In this study, we used image-based proliferation and apoptosis assays in colorectal cancer cell lines to systematically investigate the efficacy of combinations of two to six drugs that target critical oncogenic pathways. Drug pairs targeting key signaling pathways resulted in synergies across a broad spectrum of genetic backgrounds but often yielded only cytostatic responses. Enhanced cytotoxicity was observed when additional processes including apoptosis and cell cycle were targeted as part of the combination. In some cases, where cell lines were resistant to paired and tripled drugs, increased expression of antiapoptotic proteins was observed, requiring a fourth-order combination to induce cytotoxicity. Our results illustrate how high-order drug combinations are needed to kill drug-resistant cancer cells, and they also show how systematic drug combination screening together with a molecular understanding of drug responses may help define optimal cocktails to overcome aggressive cancers. Cancer Res; 76(23); 6950-63. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27659046     DOI: 10.1158/0008-5472.CAN-15-3425

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Authors:  Emilie A Chapeau; Agnieszka Gembarska; Eric Y Durand; Emeline Mandon; Claire Estadieu; Vincent Romanet; Marion Wiesmann; Ralph Tiedt; Joseph Lehar; Antoine de Weck; Roland Rad; Louise Barys; Sebastien Jeay; Stephane Ferretti; Audrey Kauffmann; Esther Sutter; Armelle Grevot; Pierre Moulin; Masato Murakami; William R Sellers; Francesco Hofmann; Michael Rugaard Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

2.  Prediction of drug combination effects with a minimal set of experiments.

Authors:  Aleksandr Ianevski; Anil K Giri; Prson Gautam; Alexander Kononov; Swapnil Potdar; Jani Saarela; Krister Wennerberg; Tero Aittokallio
Journal:  Nat Mach Intell       Date:  2019-12-09

3.  Diagonal Method to Measure Synergy Among Any Number of Drugs.

Authors:  Melike Cokol-Cakmak; Feray Bakan; Selim Cetiner; Murat Cokol
Journal:  J Vis Exp       Date:  2018-06-21       Impact factor: 1.355

4.  Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer.

Authors:  Alexandros Georgiou; Adam Stewart; David Cunningham; Udai Banerji; Steven R Whittaker
Journal:  Mol Cancer Res       Date:  2020-02-25       Impact factor: 5.852

Review 5.  Charting the Fragmented Landscape of Drug Synergy.

Authors:  Christian T Meyer; David J Wooten; Carlos F Lopez; Vito Quaranta
Journal:  Trends Pharmacol Sci       Date:  2020-02-26       Impact factor: 14.819

Review 6.  The future of antibiotics begins with discovering new combinations.

Authors:  Meilin Zhu; Megan W Tse; Juliane Weller; Julie Chen; Paul C Blainey
Journal:  Ann N Y Acad Sci       Date:  2021-07-02       Impact factor: 6.499

7.  The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.

Authors:  Florian Weinberg; Nadine Reischmann; Lisa Fauth; Sanaz Taromi; Justin Mastroianni; Martin Köhler; Sebastian Halbach; Andrea C Becker; Niantao Deng; Tatjana Schmitz; Franziska Maria Uhl; Nicola Herbener; Bianca Riedel; Fabian Beier; Alexander Swarbrick; Silke Lassmann; Jörn Dengjel; Robert Zeiser; Tilman Brummer
Journal:  EBioMedicine       Date:  2017-04-12       Impact factor: 8.143

8.  High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids.

Authors:  Evelina Folkesson; Barbara Niederdorfer; Vu To Nakstad; Liv Thommesen; Geir Klinkenberg; Astrid Lægreid; Åsmund Flobak
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

9.  Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma.

Authors:  Magdalena Rausch; Andrea Weiss; Joanna Achkhanian; Andrei Rotari; Patrycja Nowak-Sliwinska
Journal:  Br J Cancer       Date:  2020-05-22       Impact factor: 7.640

10.  Prediction of drug cocktail effects when the number of measurements is limited.

Authors:  Anat Zimmer; Avichai Tendler; Itay Katzir; Avi Mayo; Uri Alon
Journal:  PLoS Biol       Date:  2017-10-26       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.